LY3437943 (Retatrutide): discovery to clinical proof of concept (triple GLP-1/GIP/glucagon agonist, preclinical mechanism) Nature Reviews Endocrinology (2024) Multi-receptor agonists for metabolic disease (mechanism of GLP-1/GIP/glucagon co-activation) Diabetes Care (2024) Incretin-based therapies: GLP-1, GIP, and glucagon receptor pharmacology (metabolic pathways, energy expenditure) NEJM (2023) Supplementary Material Jastreboff et al
Harris SB, Kocsis G, Prager R, Ridge T, Chandarana K, Halladin N, Jabbour S
No ratio quantification
Youre not getting a plug-and-play system, but real clinical oversight
Portion-controlled, high-protein options like Clean Eatz Kitchen meals make hitting these targets effortless35g+ protein per serving, perfectly portioned, ready in minutes
Professional guidance matters Even approved medications can cause side effects and require thoughtful dosing, monitoring, and follow-up